Navigation Links
Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
Date:9/10/2009

the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell((R)) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.

For more information on Bioheart, visit www.bioheartinc.com.

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii)
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Bioheart, Inc. Announces Financial Results for First Quarter 2008
4. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
5. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
6. Bioheart, Inc. to Transfer to Nasdaq Capital Market
7. Bioheart, Inc., Added to Russell Microcap Index
8. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
9. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
10. Bioheart, Inc., Announces Management Change
11. Bioheart, Inc. Announces Results of Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
(Date:6/26/2015)... , June 23, 2015 ... announced the addition of the "Global Cancer ... offering. Market introduction of cancer biosimilar ... and commercialization potential. Chemotherapeutic drugs have dominated the ... modalities have been introduced in past few years. ...
(Date:6/25/2015)... 25, 2015 ... announced the addition of the  "2015 ... Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, ... Commercial Labs, POC Locations"  report ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , A ...
(Date:6/25/2015)... NEW YORK , June 25, 2015  The ... , Professor of Genome Sciences and Medical Genetics at ... the 2015 Pro Bono Humanum Award at the ninth ... ceremony.   The Pro Bono ... Professor King is the first woman recipient of the ...
Breaking Biology Technology:iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 3
... (Pink Sheets: BIEL), announced today that the ... sale by its,distributor, Endotherapeutics Party Limited. ... professionals of,Endotherapeutics will successfully launch ActiPatch in ... of experience in the,medical devices market and ...
... ... REDWOOD CITY, Calif., Oct. 9 Ingenuity Systems, ... science researchers,generate insights from biological and chemical information, ... to help researchers understand metabolomics data in the,context ...
... Drug Pipeline and Advancement of Clinical Programs, ... Inc.,(OTC Bulletin Board: AVGO), a late-stage biotechnology company ... today that it will be a presenting company ... held October 9-11, 2007 at the,Palace Hotel of ...
Cached Biology Technology:Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 2Avicena to Present at 4th Annual BIO InvestorForum Conference 2
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces that its leading ... to media at Digital Experience! @ NYC June 18th. ... of the latest innovation in technology to over 300 of ... held at the Metropolitan Pavilion in New York ...
(Date:6/10/2015)... , June 10, 2015 ... "3D Sensor Market by Technology (Ultrasound, TOF, Structured ... (consumer Electronics, Entertainment, Automotive) and by Geography - ... by MarketsandMarkets, the market is expected to reach ... of 25.51% between 2015 and 2020. ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... clinical data featuring its Precision Cancer Monitoring SM platform ... Liquid Biopsies conference in San Diego, CA ... Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... June 13-16. "We continue to advance our ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... studied the marine trophic network in Mauritania, on the ... heavily exploited fishing area, as well as being home ... marine mammal the monk seal and the Atlantic ... industrial and traditional fishing activities along the coast are ...
... -- NASA,s newest Earth-observing research mission is nearing launch. ... the sun and tiny atmospheric particles called aerosols affect ... long-term solar measurements needed to address key uncertainties about ... from Vandenberg Air Force Base in California on Feb. ...
... a hormone best known for stimulating the production of red ... published by Cell Press in the January 27th issue of ... contrasting influences on infectious and inflammatory diseases and may be ... is a cytokine hormone that stimulates the production of red ...
Cached Biology News:Monk seal and hump-backed dolphin are threatened by fishing activities off coast of Mauritania 2NASA prepares to launch next Earth-observing satellite mission 2NASA prepares to launch next Earth-observing satellite mission 3Red blood cell hormone modulates the immune system 2
MAb to Myoglobin Cardiac...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: